Improving Sleep and AD Biomarkers

NAActive, not recruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

December 15, 2023

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions
Mild Cognitive ImpairmentAlzheimer Disease
Interventions
DIETARY_SUPPLEMENT

Citicoline Supplement

Participants with MCI will receive dietary citicoline supplements. Subjective sleep measures will be measured via the Pittsburgh Sleep Quality Index (for measurement of sleep quality) and Epworth Sleepiness Scale (for measurement of sleepiness). Cognition will be measured by Rey Auditory Verbal Learning Test (RAVLT), Trail Making Test (TMT) Parts A \& B, and the Montreal Cognitive Assessment (MOCA). Participants will complete all questionnaires at baseline and at follow-up at 3 months. Participants will undergo a blood draw of approximately 20 ml at baseline and at follow-up.

OTHER

Placebo

Participants with MCI will receive a placebo supplement. Subjective sleep measures will be measured via the Pittsburgh Sleep Quality Index (for measurement of sleep quality) and Epworth Sleepiness Scale (for measurement of sleepiness). Cognition will be measured by Rey Auditory Verbal Learning Test (RAVLT), Trail Making Test (TMT) Parts A \& B, and the Montreal Cognitive Assessment (MOCA). Participants will complete all questionnaires at baseline and at follow-up at 3 months. Participants will undergo a blood draw of approximately 20 ml at baseline and at follow-up.

Trial Locations (2)

30322

Emory University School of Nursing, Atlanta

30329

Goizueta Alzheimer's Disease Research Center, Atlanta

All Listed Sponsors
collaborator

National Institute on Aging (NIA)

NIH

lead

Emory University

OTHER